ArticleCancer science2022

Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.

Atae Utsunomiya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.